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Regulatory T (Treg) cells are essential for normal immune surveillance systems, and
their dysfunction leads to development of diseases, such as autoimmune disorders.
CD4+CD25+ Treg cells are well-known suppressive cells, which express the transcrip-
tion factor Foxp3, are indispensable for the maintenance of immune self-tolerance and
homeostasis by suppressing aberrant or excessive immune response. Other Foxp3− Treg
cells include Tr1, Th3, CD8+CD28−/−, and Qa1-restricted T cells; however, the contribution
of these Treg cells to self-tolerance, immune homeostasis as well as preventing autoim-
munity is not well defined. Here, we discuss the phenotypes and function of Foxp3+ Treg
cells and the potential use of such Treg cells against rheumatoid arthritis (RA). Of note,
even though most expanded populations of Foxp3+ Treg cells exhibit suppressive activity,
tissue-associated or antigen-specificTreg cells appear superior in suppressing local autoim-
mune disorders such as RA. In addition, utilizing tissue-associated Foxp3+ Treg cells from
stem cells may stable Foxp3 expression and avoid induction of a potentially detrimental
systemic immunosuppression.
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INTRODUCTION
Rheumatoid arthritis (RA) is a chronic autoimmune disorder,
which has approximately 1% prevalence in the industrialized
world, and is described by pain and stiffness of the joints, and
inflammation of the synovial membrane. This systematic autoim-
mune disorder results in the accumulation of inflammatory cells
such as T cells, B cells, and macrophages in the inflamed joints,
which can lead to persistent synovitis and tissue destruction, typi-
cally articular cartilage destruction. Being a disabling and painful
condition, RA often causes loss of mobility and function, and is
commonly accompanied by substantial comorbid conditions in
the cardiovascular, neurologic, and metabolic systems (1). The
autoantigens are still unidentified in spite that RA is considered
as autoimmune disease. The main cause of autoimmune disor-
der like RA is the failure in the maintenance of immunological
self-tolerance. There are multiple mechanisms for maintaining
the self-tolerance within the immune system. It is considered that
autoreactive T cells and B cells are vital for the pathogenesis of
RA. Autoreactive T cells are mainly deleted in the thymus; how-
ever, this process is not strict. Nevertheless, autoreactive T cells
can escape into the peripheral immune system, and subsequent
activation will cause autoimmune pathological disorders (2).
The etiological factor for the development of autoimmune dis-
order remains unclear; however, the progression of the RA disease
is associated with synovial inflammation, which can develop to a
Pannus (thickening synovial tissue) and damage the surrounding
cartilage and bone. Plasmatic cells infiltrate into the joint and
produce antibodies that form aggregates of IgG. In order, the
immune system recognizes these IgG aggregates as foreign anti-
gens. Within the synovial membrane, plasmatic cells, T cells, B
cells, dendritic cells (DCs), and macrophages develop lymphoid
follicle-like constructions, and start to create antibodies against
these constructions recognized as rheumatoid factor RF (3). The
IgM class is the most significant type of RF in regards to RA that
emerges in 70–80% of patients. During the development of the
disease, a wide variety of cells, including B cells, macrophages,
DCs, neutrophils, fibroblasts, and granulocytes profoundly infil-
trate into the normal and relatively avascular synovium. However,
the concept for the pathogenic events that are critical for the trig-
gers for the onset of diseases remains undetermined. In general, RA
is induced by interactions of multiple factors, including genetic,
biomechanical, and environmental factors, neuro-immune inter-
actions, and impaired articular microvascular function (4). Up
to now, by using the genome-wide association studies, a num-
ber of genetic loci have been suggested to be associated with RA
susceptibility and severity (3, 5, 6).
The immune system can defend against pathogenic attack, and
is responsible for maintaining effective immune response as well
as promoting an adequate inflammatory response. Regulatory T
(Treg) cells, formerly known as suppressor T cells, are a devel-
opmentally and functionally distinct T cell subpopulation that
modulates the immune system, retains tolerance to self-antigens,
and eliminates autoimmunity. CD4+CD25+ suppressor T cells
are well-known Treg cells that express the transcription factor
forkhead box P3 (Foxp3), are indispensable for the maintenance
of immune self-tolerance and homeostasis by suppressing aber-
rant or excessive immune response. Other Foxp3− suppressor
T cells include Tr1, Th3, CD8+CD28−/−, and Qa1-restricted T
cells; however, the contribution of these Treg cells to self-tolerance,
immune homeostasis as well as preventing autoimmunity is not
well defined. The main functions of Foxp3+ Treg cells are to
migrate into inflammation sites and suppress various effector lym-
phocytes, especially the subsets of CD4+ helper T (Th) cells: Th1,
Th2, Th17, and follicular Th cells. Over the past decade, a number
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of studies have addressed that the majority of the Foxp3+ Treg cells
are produced in the thymus as an antigen-primed and functionally
mature T cell subpopulation specialized for immune suppression.
However, some of Foxp3+ Treg cells differentiate from naive con-
ventional T cells in the periphery under certain condition (7). The
characteristics of different Treg cell subsets are briefly described in
Table 1.
CD4+CD25+ Treg CELL FUNCTION IN RHEUMATIC DISEASE
Thymic selection results in the appearance of T cells with two types
of T cell receptor (TCR). The majority express αβ chains in the
TCR, forming unique structure on each T cell. αβ T cells repre-
sent mature T cells that circulate through the secondary lymphoid
organs and develop adaptive immune response. Some other frac-
tion of T cells express γδ chains in TCR, reside in skin and mucosal
surfaces that play a role in the initial response to microbial inva-
sion. On the basis of lineage marker and functional activities, αβ
T cells are subdivided into several groups, including CD4+ and
CD8+, or naive, effector, and memory T cells. Naive T cells are
the most homogenous representative of CD4+ and CD8+ subsets.
The activated CD4+ T cells can be subdivided into Th1, Th2, Th17,
and Treg cell subsets based on production of signature cytokines.
There are two main classes of CD4+CD25+ Treg cells: natu-
rally occurring Treg (nTreg) cells and induced or adaptive Treg
(iTreg) cells. nTreg cells are CD4+CD25+Foxp3+ Treg cells that
develop in the thymus. iTreg cells are induced Foxp3+ Treg cells
converted from Foxp3− T effectors (Teffs) (8). There are mul-
tiple signaling pathways that are involved in the activation and
control of T cell responses. There are no unique surface markers
for Treg cells; however, Treg cells are usually distinguished by the
expression of CD25 (the alpha chain of the IL-2 receptor), CTLA-4
(CD152, cytotoxic T-lymphocyte antigen 4), and glucocorticoid-
induced tumor-necrosis-factor-receptor-related protein (GITR).
These proteins are expressed not only on Treg cells but also on
activated T cells that make complications for their use as markers
of Treg cells. It remains unclear how the Treg cells are generated and
the mechanisms that relate to their function. Nevertheless, CTLA-
4 and TGF-β are critical in activity of Treg cells. CTLA-4−/− or
TGF-β−/− mice have a more extensive pathology than those lack-
ing CD4+CD25+ Treg cells, although such Treg cells can function
in the absence of TGF-β production or signaling. In general, the
signaling mechanisms by which Treg cells are developed and exert
their suppressive function still need to be determined.
The transcription factor Foxp3 is highly expressed in lym-
phoid tissues such as CD4+ T cells; however, approximately
undetectable in B cells and CD8+ T cells. Foxp3 is similar to
other genes such as CTLA-4, OX40, and GITR, is a gene asso-
ciated with cell activation and the Treg lineage. Foxp3 is not
expressed in CD4+CD25− Th cells upon stimulation. Foxp3 is
the most specific gene for the lineage of Treg cells as compared
with other associated genes like GITR or CTLA-4. Being an X
chromosome-encoded transcription factor, Foxp3 is indispensible
for both development and function of Treg cells. Mice mutated
in Foxp3 as well as patients with immune dysregulation polyen-
docrinopathy, enteropathy, and X chromosome-linked syndrome
(IPEX) result in the development of complex autoimmune dis-
eases due to the deficiency of Treg cells. When manipulated to
ectopically express Foxp3, T cells acquire the phenotype of Treg
cells. Furthermore, approximately 90% decrease of Foxp3 pro-
tein expression due to destabilizing alterations in the 3′ UTR of
the Foxp3 messenger RNA (mRNA), thereby destabilizing mRNA,
results in significantly impaired Treg cell-mediated suppression,
demonstrating that the amount of Foxp3 protein directly cor-
relates to the function of Treg cells (9). Constitutive expression
of Foxp3 is fundamental for the maintenance of the suppressive
function of Treg cells (10).
Table 1 | Characteristics of differentTreg cell subsets.
Cell type Phenotype Mechanism Origin
nTreg cells Foxp3+CTLA4+TNFR Contact dependent, CTLA4, IL-10, and TGF-β1 Thymus
SF18+IL7Rlow
CD25hi (mouse)
CD25very hi (human)
nTreg cells (activated) Foxp3+HLA− Contact dependent Expansion of natural Treg cells
DR+CD69+
Granzyme B+ (mouse)
Granzyme A+ (human)
iTreg cells Foxp3+CTLA4+TNFR Contact dependent and in some cases
TGF-β1 dependent
Conversion and/or expansion
of naive CD4+ T cellsSF18+
TH3 cells Foxp3− TGF-β and or/IL-10 Periphery
Tr1 cells Foxp3− IL-10 Periphery
IFNγ− (mouse)
IFNγlow (human)
CD8+ T cells CD28+/− Cell contact−, LILRB4−, and LILRB2
dependent
Periphery
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Although the precise signaling mechanisms regulating Foxp3
expression are not fully understood, TGF-β, IL-2, or TCR stimula-
tion of T cells results in increased Foxp3 expression. This is most
likely modulated by the demethylation of the Foxp3 promoter or
conserved non-coding regions in the Foxp3 locus (11). In addition,
multiple transcription factors, including cAMP response element
modulator (CREB)/activating transcription factors (ATF), Ets-1
(protein C-ets-1), forkhead box protein O1 (Foxo1), forkhead box
protein O3 (Foxo3), and signal transducer and activator of tran-
scription 5 (STAT5), regulate Foxp3 transcription (12, 13). It is
not fully clear whether Foxp3+ Treg cells can lose Foxp3 expres-
sion and suppressive function, as well as whether Foxp3+ Treg
cells exhibit characteristics of other Th cell subsets. A number
of studies in which Foxp3+ Treg cells were adoptively transferred
into lymphopenic mice demonstrated that approximately 10–50%
of the transferred Treg cells lost Foxp3 expression (14–16). Fur-
thermore, Treg cells from both the periphery and the thymus
were converted into Th17 cells upon stimulation with anti-CD3,
anti-CD28, and IL-6, demonstrating a degree of plasticity (17).
In addition, Foxp3+ Treg cells can be converted to a Foxp3 Th1
cell phenotype upon Toxoplasma infection (18). In fact, Foxp3
can be polyubiquitinated; however, the regulation of this process
and the modulators remain elusive (19–21) Deubiquitinating
enzyme (DUB) ubiquitin-specific-processing protease 7 (USP7,
also known as HAUSP, ubiquitin carboxyl-terminal hydrolase 7
or herpesvirus-associated ubiquitin-specific protease) is active in
primary Treg cells and associates with Foxp3. Ectopic expression
of USP7 specifically decreased Foxp3 polyubiquitination, resulting
in increased Foxp3 expression. Conversely, knockdown of USP7
resulted in decreased Foxp3 expression. Furthermore, the function
of Treg cells was noticeably decreased when USP7 was knocked
down or when DUB activity was inhibited both in vitro and
in vivo (22). The manipulation of Foxp3 ubiquitination provides
a method for temporally controlling the expression of Foxp3 in T
cells, thereby regulating the numbers and function of Treg cells.
CD4+CD25+ Treg cells comprise approximately 5–10% of the
mature CD4+ T cells in mice and humans, and approximately 1–
2% of CD4+ Treg cells are detectable in peripheral blood. Murine
and human nTreg cells are phenotypically similar on the basis
of surface markers, expressing MHC-class II molecules, CD25,
CD122, CD132, GITR, CTLA-4, PD-L1, CD62, CD38, CD45RO,
and Foxp3. Although both nTreg cells can use the cell–cell contact
mechanism to mediate their suppressive function, murine nTreg
cells are via a granzyme-B-dependent and perforin-independent
pathway, while human nTreg cells are via a granzyme-A and
perforin-dependent pathway. Number of CD4+CD25+ Treg cells
in peripheral blood is differed; however, the frequency of Treg
cells is constantly higher in the synovial fluid than in the periph-
eral blood. Furthermore, Treg cells from RA patients still keep
their suppressive ability; however, these Treg cells have no capacity
to stop the production of inflammatory cytokines such as TNF-α
from monocytes or activated T cells (23). This functional defect
of Treg cells in RA was related with a high expression of TNF-α
that reduced expression of Foxp3, or resulted in defective expres-
sion of CTLA-4 (24, 25). Cell number is critical during arthri-
tis development. In many autoimmune disorders, e.g., juvenile
idiopathic arthritis, psoriatic arthritis, multiple sclerosis, systemic
lupus erythomatosus, autoimmune hepatitis, and type-1 diabetes,
the numbers and suppressive activity of circulating CD4+CD25+
Treg cells dramatically reduced (26). Despite presenting in the
joints of patients with RA, Treg cells did not possess normal
immune suppressive activity. Treg cells in the synovial fluid from
RA patients are exposed to a numbers of inflammatory cytokines;
high amounts of TNF-α secreted by the inflamed synovium into
the joint fluid likely cause the abnormal phosphorylation of Foxp3,
resulting in abnormal suppressive function of Treg cells.
The function and frequency of Treg cells can be measured in
peripheral blood as well as at the site of inflammation in arthritic
patients. Circulating Treg cells in RA patients holding mutable
functional activity, particularly with regard to the suppressive
function (27); however, at the inflamed joints, the suppressive
activity of enriched Treg cells is high and consistent (28). The
general agreement is that these are highly reactive Treg cells,
which have an increased suppressive activity (29). Similarly in
synovium of RA patients, Foxp3 DNA methylation resulted in a
higher dedication toward Treg cell lineage (30). In the inflamed
synovium of RA patients, local tissue and different immune
cells interrelate through cytokines and/or cell–cell contact. Pro-
inflammatory cytokines, e.g., TNF-α, IL-6, and antigen presenting
cells (APCs) also affect the function of Treg cells. Despite pre-
senting in large amounts and suppressive function in vitro, Treg
cells likely display different suppressive capacity in vivo, countered
by the inflammatory environment, or hampered by the resistance
from Teffs (31).
MODULATION OF CD4+CD25+ REGULATORY T CELLS
A number of therapeutic strategies have been implemented in the
clinical and many others are being developed for the treatments of
RA including: biological therapy, stem cell therapy, mesenchyme
stem cell (MSC)-based therapy, hematopoietic stem cell (HSC)-
based therapy, and Treg cell-based therapy. In the field of RA, the
biological therapy is a fairly new type of therapeutics, and is usu-
ally managed at specific biological targets, which have a function
in the inflammatory cascade. In general, these targets are TNF-
α, IL-6, the IL-1 receptor antagonist, and soluble CTLA-4. There
are three biological agents targeting TNF-α. These are infliximab,
adalimumab, and etanercept. Currently, these biological agents are
used to treating RA. Despite targeting TNF-α is a successful ther-
apeutic strategy in the treatment of RA, methotrexate (MTX), not
targeting TNF-α, is also an effective drug (28). MTX is an antifo-
late drug that suppresses purine and pyrimidine synthesis and
inhibits DNA replication. Early treatment with TNF-α inhibitors
combined with MTX has been shown to significantly improve
treatments of RA (30, 32). In addition to TNF-α and MTX, there
are some other biologic agents for treating moderate to severe RA,
including abatacept, rituximab, and tocilizumab (31, 33).
Another effective biological target of RA is IL-6. IL-6 is signif-
icantly increased in synovial fluid of RA patients, and functions
as a pro-inflammatory cytokine, which directly reduced the sup-
pressive function of Treg cells (23). In addition, IL-6 dramatically
influenced the conversion of Foxp3+ CD4 T cells into Th17 cells
(34). Th17 cells play a crucial role in RA pathology through secret-
ing IL-17. IL-17 has ability to activate a number of cells, such as
synovial fibroblasts and monocytes that were involved in causing
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joint damage (35). Neutralization of IL-17 during reactivation of
antigen-induced arthritis in animals prevented joint inflammation
and bone erosion (36). Another drug that targets IL-6 receptor
is tocilizumab, a humanized antibody that has been proven as
a successful therapy for the treatments of RA (37). Tocilizumab
can ameliorate the symptom of RA by reducing the Th17 cells,
and increasing the number of CD4+CD25+ Treg cells at the site
of inflammation. As a matter of fact, tocilizumab corrected the
balance of Th17/Treg cells in RA patients (38).
IL-1 is a central pro-inflammatory cytokine that impacts on a
number of cell types and subsequently induces bone and cartilage
destruction. IL-1 is another important biological that modulates
RA pathology. Human recombinant IL-1 receptor antagonist (IL-
1ra) can block the IL-1 mediated effects, and restore the balance of
Th17/Treg cells. Even though the exact mechanisms remain largely
unknown, the use of anakinra, an IL-1ra, as a therapy in RA was
effective and safe (39). Treg cells highly express CTLA-4, which
controls the suppressive function of Treg cells (40). CTLA-4 is
also expressed on activated T cells, however, binding to its ligands
induces opposite effects in effector and Treg cells. For example,
ligation of CTLA-4 with CD80 (B7-1) and CD86 (B7-2) inhibits
the function of Teffs but augments the suppressive capacity of
Treg cells. CTLA-4-Ig (also known as abatacept) is a human fusion
protein that consists of the extracellular domain of CTLA-4 and
the Fc portion of IgG1, which is used for the treatments of RA
patients.
In addition, nTregs and iTreg cells can directly kill autolo-
gous target cells through a CD18 and perforin-dependent man-
ner (41–43). Upon activation, nTreg cells predominantly express
granzyme-A while iTreg cells express granzyme B. Both subtypes
of Treg cells exhibit perforin-dependent cytotoxicity against a vari-
ety of autologous target cells, including CD4+ and CD8+ T cells,
CD14+ monocytes, and DCs. The mechanism by which the Treg
cell subsets recognize their targets is unclear; however, several lines
of evidence suggest that it is an MHC/TCR independent process.
The potential suppressive mechanisms of Treg cells are briefly
described in Figure 1.
Treg CELL-BASED THERAPIES IN RA
Regulatory T cells play a central role in controlling autoimmunity.
Deficiencies in the functions of Treg cells have been identified in a
number of autoimmune diseases including RA. A number of stud-
ies suggested that stem cell therapy or biological therapy induced a
potent population of CD4+CD25+ Treg cells in patients with RA
(44); however, the deficit of nTreg cells persisted in the patients
even after the treatment with anti-TNF-α (45). CD4+CD25+ Treg
cells isolated from active RA patients were capable of suppress-
ing the proliferation of conventional T cells; however, these Treg
cells could not suppress the cytokine production. It is suggested
that reduced expression and functional abnormalities in Treg cells
associated with CTLA-4 might account for the defect of Treg cells
in patients with RA (25).
After the success of the biological therapies in RA, new ther-
apeutic adventures with the goal to ultimately reach complete
clinical remission become more attractive. For reestablish the
tolerance by utilizing Treg cells, numerous studies have been per-
formed on Treg cell-based therapies. This approach can be reached
FIGURE 1 | Suppressive mechanisms ofTreg cells. Treg cells mediate
their suppressive activity by direct cell–cell contact mediated by CTLA-4 on
both Teffs and APCs, e.g., DCs. Suppressive cytokines (IL-10 and TGF-β)
suppresses DC maturation and function. Treg cells also destroy Teffs
through secreting perforin and granzyme-A.
by expansion of CD4+CD25+ Treg cells ex vivo or induction of
Treg cells in vivo. Because of the inherent resistance of Treg cells
to exogenous expansion, and large numbers of Treg cells essen-
tially required to perform the cell-based therapies, it is critical to
isolate a high number of Treg cells for exogenous expansion, and
the following adoptive transfer. However, caution is needed when
translating in vitro induction of Treg cells to in vivo application.
To make sure that Treg cells suppress Teffs at the site of inflamma-
tion, a number of strategies have been suggested to regulate the
numbers and functionality of Treg cells such as ectopic expression
or the acetylation modulation of Foxp3 (46).
Embryonic stem cells (ESCs) or induced pluripotent stem cells
(iPSCs) have the strong potential to differentiate into a number
of different cell types in the body. Different types of blood cells
including myeloid and lymphoid lineages can arise from ESCs or
iPSCs. The approach to obtain ESCs from patients is not feasible.
HSCs have a higher potential to pass the bone marrow barrier and
travel in the blood, which allows HSCs to be easily and safely
harvested from the patient blood following mobilization with
hematopoietic growth factors. Thus, the use of HSC for therapeu-
tic purposes has been widely applied in clinic, especially in HSC
transplantations. In addition,HSCs also can be generated from dif-
ferentiated cultures from ESCs and fetal-derived embryonic germ
stem cells (47). However, compared to pluripotent ESCs or iPSCs,
HSCs or MSCs have less potential for self-renewal, and the differ-
entiation declines in response to differentiation signals with each
cycle (48). In fact, the ability to expand numbers in vivo or in vitro
would be a huge boost to all current and future medical uses of
HSCs and MSCs. In contrast, iPSCs can be easily generated from
patients’ somatic cells by transduction of various transcription
factors and exhibit characteristics identical to those of ESCs (49,
50). Many genetic methods as well as the protein-based approach
have been developed to produce iPSC with potentially reduced
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risks, including that of immunogenicity and tumorigenicity (51–
53). This approach provides an opportunity to generate patient-
or disease-specific iPSCs (54–56). Because of the plasticity and
the potential for an unlimited capacity for self-renewal, iPSCs
have high potential for advancing the field of cell-based therapies
(57, 58). Recent results have shown that programing of functional
CD4+ Treg cells or CD8+ cytotoxic T lymphocytes from iPSCs can
be used for adoptive immunotherapy of cancers and autoimmune
arthritis (59–62).
Embryonic stem cells and iPSCs are exposed to a number of
signals responsible for their progression. Although the exact sig-
nals are not fully understood, part of the mechanism known to
be critical for directing T-cell fate occurs via the Notch signal-
ing pathway (63, 64). Notch is evolutionarily conserved regulating
cell fate decisions in a number of cell and tissue types. Ligand
binding by members of the Jagged or Delta-like families results
in the proteolytic cleavage and release of the intracellular frag-
ment of the Notch heterodimer. Translocation to the nucleus then
allows for its regulation of gene expression. Notch-1, specifically,
has been shown to be critical for the establishment of T-cell fate.
Loss of function results in the blockade of T cell development
and enhanced B cell production, while over-expression results in
the blockade of B cell lymphopoiesis and leads to the generation
of T cells (64). However, the intracellular signaling pathways by
which Notch signaling regulates Ag-specific PSC–Treg differenti-
ation remain unknown. Genetic modification of iPSCs with the
Foxp3 gene and an antigen-specific TCR as well as stimulation
with an in vitro Notch ligand may direct iPSC differentiation into
antigen-specific Treg cells, which produce suppressive cytokines
and inhibit other immune cell activities. Adoptive transfer of iPSC-
derived Treg cells has been shown to suppress the development of
arthritis in a murine model (62).
IMMUNOSUPPRESSION BY Treg CELL THERAPY
The transfer of ex vivo expanded Treg cells into the patients is
presently the focus of intense research to treat autoimmune dis-
orders and to suppress the occurrence of graft-versus-host disease
(GVHD) after bone marrow transplantation (65, 66). Ex vivo
expanded Treg cells were dramatically useful in the prevention
of autoimmune diseases, and in many cases, in the treatments
of ongoing inflammatory and autoimmune disorders in mice
(4). A number of mechanisms have been suggested for Treg cell-
mediated suppression, including secretion of immunosuppressive
cytokines from the Treg cells, cell contact dependent suppres-
sion, and functional modification or killing of APCs. However,
it is not clear whether Treg cells in vivo use same or different
mechanisms. Nevertheless, a number of key issues need to be
considered prior to their clinical use. First, because of the het-
erogeneity of Foxp3+ Treg cells, it is important to determine the
optimal Treg cells that should be isolated for expansion. Expan-
sion of Foxp3-expressing T cells is based on isolation of CD25
and CD127; this method usually results in contamination of non-
regulatory CD45RO+Foxp3low T cells. CD45RO+FoxP3low cells
are capable of producing pro-inflammatory cytokines, and likely
constitute 30–50% of the Foxp3+CD4+ T cells (67). Because
FoxP3 expression is crucial for the suppressive activity of Treg cells,
and CD45RA+Foxp3low naive Treg cells have the highest capacity
of maintaining the expression of Foxp3 after expansion, the subset
of CD45RA+Foxp3low naive Treg cells is the best population of
choice for isolation (68).
Second, the apoptotic properties of Treg cells should be investi-
gated because these cells may be used to modulate the ratio of Treg
to Teff cells. Treg cells are prone to die by apoptosis (69) and it is
hard to expand in cultures with high dose of IL-2 (67). In addition,
naive Treg cells are easier to expand and develop a high frequency
of functional Foxp3+ Treg cells; the use of CD45RA+Foxp3low
naive Treg cells is the best choice for the expansion of Treg cells. It
has been shown that purified naive Treg cells, when cultured with
high-dose IL-2, could give rise to inflammatory cytokine produc-
ing T cells (70). Therefore, certain cytokines and chemicals need
to be determined to enable the expansion of functional Treg cells,
which will not secrete pro-inflammatory cytokines. Rapamycin
(also known as Sirolimus/Rapamune) likely be useful as a com-
ponent as it substantially increases the purity of Treg cells by
eliminating non-Treg cells (71).
To onset the development and pathogenesis of arthritis in mice,
a number of cytokines are regarded to play a crucial role (72).
Among them, IL-17 has an important role; IL-17 is a T cell derived
pro-inflammatory cytokine produced by TCRα/β+CD4−CD8−
thymocytes, as well as activated CD4+ and CD4+CD45RO+mem-
ory T cells (73). IL-17 is involve in the development of RA because
of the existence in the synovial fluid of RA patients and the pro-
duction from T cell clones established from RA patients (74). IL-17
played a role in the early and late stages of collagen induced arthri-
tis (75). Adoptively transfer of engineered Treg cells substantially
decreased inflammatory knee swelling and a significant reduction
of Th17 cells in the draining lymph nodes (76). Treg cells were
capable of limiting the detrimental effects of Th17 cells by reduc-
ing accumulation at the site of inflammation and in the draining
lymph nodes (77). However, Treg cells might be inefficient sup-
pressors of Th17 cells (25, 26). Taken together, a successful therapy
using Foxp3+ Treg cells (both nTreg and iTreg cells) depends on
how Treg cells are prepared, the purity of the Treg cells, and how
the Treg cells are maintained as a functionally stable cells in vivo
as well as in vitro expanded.
For a successful and potential immunotherapy using Treg cells,
Ag specificity of Treg cells are highly recommended. The impor-
tance of antigen specificity is a strong indication where high doses
of polyclonal Treg cells fail to reverse ongoing autoimmunity. Anti-
gen specificity is required for Treg cell to home or retained at the
appropriate site and exerts active suppression. A retroviral trans-
duction protocol in which OTII TCR genes were transduced in
primary Treg cells and in CD4+ T cells allows these cells to redi-
rect the specificity without the needs for lengthy in vitro culture.
Within 3 days, their redirected Treg cells and converted CD4+
T cells were available for adoptive transfer into recipient mice,
where they engrafted efficiently, maintained their phenotype, and
suppressed arthritic joint inflammation in an antigen dependent
fashion (76). Foxp3 transduction of naive CD4+ T cells can con-
vert these cells into functional Foxp3+ Treg cells that prevent or
suppress the development of a number of autoimmune diseases
in animals (78–80). Because of the excellent capacity of stem cell-
derived Treg cells in suppression of autoimmunity (62), generation
of antigen-specific Foxp3+ Treg cells from stem cells such as iPSCs
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and HSCs may open a new area in Treg cell-based immunotherapy
in transplantation and autoimmune disorders.
ADVANTAGES AND DISADVANTAGES FOR THE USE OF Treg
CELL-BASED THERAPY
Reestablishing self-tolerance in autoimmunity depends on self-
reactive Treg cells. The advantages of Treg cell-based immunother-
apy over conventional treatments are numerous. These benefits
include: (1) the potential for antigen specificity with the lack
of general immunosuppression; (2) the possibility of inducing
long-lasting regulation in vivo; and (3) custom-made product
that can be designed for each patient, with very limited or absent
side effects. However, due to the lack of Treg cell specific surface
antigens, purification of a more comprehensive Treg cell subset
increases the contamination by the non-regulatory Teffs. Although
the therapeutic potential for Treg cell-based immunotherapy is
now well established in animal models (81–87), to date, such ther-
apy has not been directly applied to suppress autoimmunity in
humans.
There are a number of problems and limitations in generating
a large number of Treg cells, in spite of the growing number of
methods for isolating Treg cells. No approach or method has been
established to isolate the population of Treg cells with 100% speci-
ficity. In addition to the issue of isolation, the survival of Treg cells
is another critical factor in Treg cell-based therapies. Treg cells are
disposed to apoptosis in the absence of certain cytokines (e.g., IL-
2) since Treg cells do not secrete IL-2, and are essentially dependent
on other cells (88). Also, Treg cells are prone to apoptosis because
of the low expression of the bcl-2 family proteins. Bcl-xL is an
anti-apoptotic protein that can sustain the survival of T lympho-
cytes (88). β-catenin promoted the survival of Treg cells in vitro
without changing their anergic state or suppressive function by
regulating expression of anti-apoptotic bcl-xL (89). Indeed, bcl-
xL is involved in the development and function of Treg cells by
inducing the expression of Foxp3, CTLA-4, TGF-β, and repressing
the programed death receptor-1 (PD-I) expression (90, 91). Foxp3
and bcl-xL cooperatively promote the survival of Treg cells and
prevent arthritis development because of the increased survival of
Treg cells (80). These approaches likely induce the differentiation
and survival of Treg cells, and result in the persistence of Treg cells.
In addition, there are several unsettled issues regarding the
function of Treg cells in rheumatic diseases. These unresolved
questions significantly limit the potential use of Treg cell-based
therapies in clinic. For instance, it remains unclear whether the
existed effects of Treg cell-based therapies redirect the fundamental
mechanism that donates to medical progress. In fact, the differ-
ences in the compartment of Treg cells may not be directly involved
in the improvement of symptoms. Assessment of the function of
Treg cells is also an obstacle, because there is no specific surface
marker of Treg cells in humans, and highly activated T cells also
transiently express Foxp3. Furthermore, the accessibility of the site
of inflammation in humans is limited. Of note, most investigations
are studies in the periphery, which possibly will not uncover the
interactions occurring at the site of inflammation (92).
CONCLUSION
Due to the plasticity and possibly infinite ability for self-renewal,
stem cell-derived CD4+CD25+ Treg cells likely are applicable for
Treg cell-based immunotherapy, such as autoimmune disorders.
Several questions remain: (i) how to direct the differentiation of
Treg cells, (ii) how to obtain a large number of functional Treg
cells, and (iii) which type of stem cells can be feasibly applicable
for individual use. Stem cell or their offspring likely is an optimal
option for the use of Treg cell-based therapies. iPSCs have great
potential as a source for the generation of antigen-specific Treg
cells to be utilized in personalized therapies. However, significant
challenges remain to bring the use of stem cell-based technologies
into the clinic to treat destructive chronic diseases like RA.
More also needs to be known about the effects of standard ther-
apy on Treg cells, because the precise contribution of Treg cells to
the pathogenesis of RA remains unclear, even Treg cells play an
important role. Regarding MTX, it is still controversial that Treg
cells are impacted by the treatments of MTX. With regards to tar-
geting the pro-inflammatory cytokines TNF-α, IL-6, IL-1, and the
costimulatory molecule CTLA-4, most investigations strengthen a
stimulating effect of blocking activity on Treg cells. This under-
scores the importance of further studies on the effects of current
therapies on the function of Treg cells, which could eventually lead
to the therapeutic applications by utilizing Treg cells.
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